66,475 Doximity, Inc. $DOCS Shares Acquired by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP increased its position in shares of Doximity, Inc. (NYSE:DOCS) by 17,401.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 66,857 shares of the company’s stock after acquiring an additional 66,475 shares during the quarter. Fulcrum Asset Management LLP’s holdings in Doximity were worth $1,773,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Brighton Jones LLC acquired a new stake in shares of Doximity in the third quarter worth $239,000. StoneX Group Inc. purchased a new position in shares of Doximity during the third quarter valued at $206,000. Parallel Advisors LLC raised its position in Doximity by 241.4% during the third quarter. Parallel Advisors LLC now owns 8,436 shares of the company’s stock valued at $239,000 after buying an additional 5,965 shares during the period. Chicago Partners Investment Group LLC acquired a new position in Doximity during the third quarter valued at $383,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Doximity in the 3rd quarter worth about $45,000. Institutional investors and hedge funds own 87.19% of the company’s stock.

Insider Buying and Selling at Doximity

In other news, Director Watkin Phoebe L. Yang sold 1,290 shares of the stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $26.71, for a total transaction of $34,455.90. Following the transaction, the director owned 24,744 shares in the company, valued at $660,912.24. This represents a 4.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kira Wampler sold 2,000 shares of the firm’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $32.89, for a total transaction of $65,780.00. Following the transaction, the director owned 27,923 shares in the company, valued at $918,387.47. This represents a 6.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 24,471 shares of company stock valued at $761,545 over the last three months. 31.80% of the stock is owned by insiders.

Key Headlines Impacting Doximity

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Some analysts have raised Doximity’s price targets, including Canaccord Genuity to $40, and Needham reiterated its Buy rating. A recent report also highlighted adoption of Doximity’s AI search products by 16 of the top 20 pharmaceutical companies and 34% year-over-year growth in quarterly active workflow prescribers. Analyst price target report Doximity long-term investor takeaways
• Neutral Sentiment: Director Timothy Cabral sold 10,721 shares for about $375,000. The transaction was made under a pre-arranged Rule 10b5-1 plan, which may make it less informative as a signal about his current outlook. Insider transaction report
• Negative Sentiment: Multiple law firms publicized a securities class action covering shares purchased from August 8, 2024, through May 13, 2026, with a November 16 deadline to seek lead-plaintiff status. The complaint alleges Doximity misled investors about market-share losses, competition and advertising practices, including reliance on lower-engagement formats, as well as revenue and growth trends. These claims have not been proven, but the litigation adds uncertainty and could weigh on sentiment. Class action allegations and deadline Advertising disclosure allegations

Doximity Price Performance

Shares of DOCS stock opened at $32.45 on Wednesday. Doximity, Inc. has a fifty-two week low of $17.15 and a fifty-two week high of $54.04. The stock’s 50-day moving average is $29.33 and its two-hundred day moving average is $25.43. The firm has a market cap of $5.78 billion, a P/E ratio of 42.69, a PEG ratio of 34.25 and a beta of 1.29.

Doximity (NYSE:DOCS) last announced its quarterly earnings results on Thursday, November 5th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.17. The business had revenue of $174.54 million during the quarter. Doximity had a return on equity of 15.80% and a net margin of 21.12%. The firm’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.45 earnings per share. As a group, research analysts expect that Doximity, Inc. will post 0.74 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on DOCS shares. Weiss Ratings upgraded Doximity from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, October 6th. Freedom Capital downgraded Doximity from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 8th. Evercore set a $35.00 price target on shares of Doximity in a research report on Tuesday, September 29th. Wells Fargo & Company lowered shares of Doximity from an “equal weight” rating to an “underweight” rating and set a $18.00 price target for the company. in a research report on Monday, August 10th. Finally, Stifel Nicolaus set a $27.00 price target on shares of Doximity in a report on Tuesday, September 8th. Eight analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, Doximity presently has a consensus rating of “Hold” and an average target price of $30.45.

About Doximity

Doximity, Inc. operates a digital platform designed for medical professionals, including physicians and other clinicians. Its services support professional networking, medical news and research discovery, career development, and communication among healthcare professionals. The company also offers clinical workflow tools, including Doximity Dialer, which enables clinicians to make calls and conduct video visits using a work number, as well as digital fax and document services. Doximity provides marketing and recruitment solutions to healthcare organizations and life sciences companies.